Ludlow Capital Adds Sinovac to China Small Cap Index
Wednesday July 19, 11:39 am ET
BEIJING, July 19 /Xinhua-PRNewswire-FirstCall/ -- Sinovac Biotech Ltd. (Amex: SVA
), a leading provider of biopharmaceutical products in China, announced today that it has been added as a component of the Ludlow China SmallCap Index. Gerry Salazar, President of the Ludlow SmallCap China Index commented, "The launch of the Ludlow China SmallCap Index now gives both institutional and individual investors a gauge to track the overall performance of small cap Chinese equities."
Mr. Weidong Yin, Chief Executive Officer of Sinovac, remarked, "We are honored to be recognized by Ludlow Capital as one of the leading China-based small cap companies traded in the U.S."
In 2006, Sinovac will continue to focus its marketing efforts on domestic sales, particularly its inactivated hepatitis A vaccine, Healive. Sinovac is increasing the production and sales of Healive to capture a larger market share in anticipation of live attenuated hepatitis A vaccines exclusion in China by the National Institute for the Control of Pharmaceutical and Biological Products (NICPBP), effective January 1, 2006. Sinovac also expects to begin sales of its proprietary influenza vaccine, Anflu, in the product's first full flu sales season.
About Ludlow China SmallCap Index
The Ludlow Small Cap China Index is a basket of some of the top US traded OTC and small cap Chinese stocks. The Index provides institutional and individual investors a gauge for tracking the day-to-day performance of small cap Chinese stocks in a diversified basket. The index is designed for investors who have a long-term bullish outlook on China's emerging small cap market. The Ludlow China Index is owned and operated by Ludlow China Fund, Inc., based in New York City. For more information on the Ludlow China SmallCap Index and components visit www.ludlowcapital.com/indices/
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's vaccines include Healive(TM) (hepatitis A), Bilive(TM) (combined hepatitis A and B) and Anflu(TM) (influenza). Sinovac is currently developing human vaccines against the H5N1 strain of pandemic influenza, Japanese encephalitis and SARS.
Safe Harbor Statement
This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward- looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.
Craig H. Bird
Segue Investor Relations
Phone: (215) 885 - 4981
Fax: (215) 885 - 4982
Contact: Ludlow China Index
Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of biomedical products that protect against human diseases.
SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected hand-foot-mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, mumps, etc.
The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under "Category 1 Preventative Biological Products" and commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO.
SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program.
SINOVAC continually dedicates itself to pipeline development including but not limited to new technology, new vaccines as well as other biomedical products. We will constantly explore global opportunities of strategic expansion.
For more information, please visit the Company’s website at www.sinovac.com.
Sinovac Biotech Ltd.